Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirexatamab
- Development stage
- Phase 2
- Lead developer
- Leap Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sirexatamab is a monoclonal antibody targeting Dickkopf-1 (DKK1), developed as an anti-cancer agent. It is being investigated primarily for the treatment of advanced microsatellite stable (MSS) colorectal cancer, particularly in patients with high DKK1 expression. Sirexatamab has been studied in combination with bevacizumab and chemotherapy, where it demonstrated improved overall response rates and progression-free survival compared to control arms, especially in biomarker-selected populations. The drug’s mechanism involves binding to DKK1, a modulator of Wnt signaling implicated in tumor growth and immune evasion. Sirexatamab is not yet approved but has shown promising results in phase 2 clinical trials.
- Brand names
- Sirexatamab
- Other names
- DKN-01DKN01DKN 01LY2812176LY-2812176LY 2812176
02
Targets
DKK1 (Dickkopf-related protein 1)
Beyond the preview
Go deeper on sirexatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirexatamab.